• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection

tetano

Editor, Senior Moderator
Mucosal Immunol. 2019 Oct 9. doi: 10.1038/s41385-019-0206-9. [Epub ahead of print] [h=1]Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection.[/h]
Hebert KD[SUP]1[/SUP], Mclaughlin N[SUP]1[/SUP], Galeas-Pena M[SUP]1[/SUP], Zhang Z[SUP]1[/SUP], Eddens T[SUP]2[/SUP], Govero A[SUP]1[/SUP], Pilewski JM[SUP]3[/SUP], Kolls JK[SUP]4[/SUP], Pociask DA[SUP]5[/SUP].
[h=3]Author information[/h] 1 Department of Pulmonary Critical Care and Environmental Medicine, Tulane University School of Medicine, New Orleans, LA, USA. 2 Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 15224, USA. 3 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 4 Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, LA, USA. 5 Department of Pulmonary Critical Care and Environmental Medicine, Tulane University School of Medicine, New Orleans, LA, USA. dpociask@tulane.edu.

[h=3]Abstract[/h] The seasonal burden of influenza coupled with the pandemic outbreaks of more pathogenic strains underscore a critical need to understand the pathophysiology of influenza injury in the lung. Interleukin-22 (IL-22) is a promising cytokine that is critical in protecting the lung during infection. This cytokine is strongly regulated by the soluble receptor IL-22-binding protein (IL-22BP), which is constitutively expressed in the lungs where it inhibits IL-22 activity. The IL-22/IL-22BP axis is thought to prevent chronic exposure of epithelial cells to IL-22. However, the importance of this axis is not understood during an infection such as influenza. Here we demonstrate through the use of IL-22BP-knockout mice (il-22ra2[SUP]-/-[/SUP]) that a pro-IL-22 environment reduces pulmonary inflammation during H1N1 (PR8/34 H1N1) infection and protects the lung by promoting tight junction formation. We confirmed these results in normal human bronchial epithelial cells in vitro demonstrating improved membrane resistance and induction of the tight junction proteins Cldn4, Tjp1, and Tjp2. Importantly, we show that administering recombinant IL-22 in vivo reduces inflammation and fluid leak into the lung. Taken together, our results demonstrate the IL-22/IL-22BP axis is a potential targetable pathway for reducing influenza-induced pneumonia.


PMID: 31597930 DOI: 10.1038/s41385-019-0206-9
 
Back
Top Bottom